General model for estimation of the inhibition of protein kinases using Monte Carlo simulations

被引:39
作者
Tominaga, Y [1 ]
Jorgensen, WL [1 ]
机构
[1] Yale Univ, Dept Chem, New Haven, CT 06520 USA
关键词
D O I
10.1021/jm0304358
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Monte Carlo statistical mechanics simulations were used in combination with the extended linear response (ELR) approach to develop a model to predict the activities of kinase inhibitors. One hundred forty eight inhibitors of three protein kinases, cyclin-dependent kinase 2 (CDK2), lymphocyte-specific kinase (Lck), and p38 mitogen-activated protein kinase were considered. The inhibitor sets for the individual kinases were analyzed first, and ELR models using only three descriptors were obtained with correlation coefficients, r(2), of 0.7-0.8. Models for each pair of kinases were then developed and used to predict the activities of the inhibitors for the remaining kinase with resultant q(2) values of 0.71 (CDK2), 0.70 (Lck), and 0.54 (p38). Finally, the three datasets were combined to yield a general ELR model for kinase inhibition; with just three physically reasonable descriptors, EXX, DeltaHB(total), and DeltaSASA, the r(2) and leave-one-out q(2) are 0.69 and 0.67. The optimization of the model was confirmed using a genetic algorithm. The descriptors reflect the structural requirements for strong inhibition: good steric and electrostatic complementarities between inhibitor and protein, limited loss of hydrogen bonds for the inhibitor upon binding, and increased burial of surface area of the inhibitor.
引用
收藏
页码:2534 / 2549
页数:16
相关论文
共 57 条
[1]   NEW METHOD FOR PREDICTING BINDING-AFFINITY IN COMPUTER-AIDED DRUG DESIGN [J].
AQVIST, J ;
MEDINA, C ;
SAMUELSSON, JE .
PROTEIN ENGINEERING, 1994, 7 (03) :385-391
[3]   Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): Design, synthesis, enzymatic activities, and X-ray crystallographic analysis [J].
Bramson, HN ;
Corona, J ;
Davis, ST ;
Dickerson, SH ;
Edelstein, M ;
Frye, SV ;
Gampe, RT ;
Harris, PA ;
Hassell, A ;
Holmes, WD ;
Hunter, RN ;
Lackey, KE ;
Lovejoy, B ;
Luzzio, MJ ;
Montana, V ;
Rocque, WJ ;
Rusnak, D ;
Shewchuk, L ;
Veal, JM ;
Walker, DH ;
Kuyper, LF .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (25) :4339-4358
[4]   The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases [J].
Brown, NR ;
Noble, MEM ;
Endicott, JA ;
Johnson, LN .
NATURE CELL BIOLOGY, 1999, 1 (07) :438-443
[5]   Synthesis and SAR of novel imidazoquinoxaline-based Lck inhibitors: Improvement of cell potency [J].
Chen, P ;
Iwanowicz, EJ ;
Norris, D ;
Gu, HH ;
Lin, J ;
Moquin, RV ;
Das, J ;
Wityak, J ;
Spergel, SH ;
de Fex, H ;
Pang, SH ;
Pitt, S ;
Shen, DR ;
Schieven, GL ;
Barrish, JC .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (21) :3153-3156
[6]   Discovery and initial SAR of imidazoquinoxalines as inhibitors of the Src-family kinase p56Lck [J].
Chen, P ;
Norris, D ;
Iwanowicz, EJ ;
Spergel, SH ;
Lin, J ;
Gu, HH ;
Shen, ZQ ;
Wityak, J ;
Lin, TA ;
Pang, SH ;
De Fex, HF ;
Pitt, S ;
Shen, DR ;
Doweyko, AM ;
Bassolino, DA ;
Roberge, JY ;
Poss, MA ;
Chen, BC ;
Schieven, GL ;
Barrish, JC .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (10) :1361-1364
[7]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[8]   Protein kinases - the major drug targets of the twenty-first century? [J].
Cohen, P .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) :309-315
[9]   INFLAMMATORY CYTOKINES - INTERLEUKIN-1 AND TUMOR-NECROSIS-FACTOR AS EFFECTOR MOLECULES IN AUTOIMMUNE-DISEASES [J].
DINARELLO, CA .
CURRENT OPINION IN IMMUNOLOGY, 1991, 3 (06) :941-948
[10]   Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717 [J].
Dreyer, MK ;
Borcherding, DR ;
Dumont, JA ;
Peet, NP ;
Tsay, JT ;
Wright, PS ;
Bitonti, AJ ;
Shen, J ;
Kim, SH .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (04) :524-530